Kibron PLDscreen vs. cell-based assays

Kibron PLDscreen requires minimal manual labor and working space, and greatly diminishes the need for costly and labor intensive cell-based assays for phospholipidosis. The results from PLDscreen are obtained in real time, providing immediate feedback to the drug development team.

Comparing the results from Kibron PLDscreen and a cell-based assay (see below) reveals an excellent correlation between these two sets of data. However, unlike the cell-based assay, PLDscreen does not give false negatives. Accordingly, the phospholipidosis-inducing potential of gentamicin and ketoconazole is readily revealed by PLDscreen, while these compounds produce no effect in the cell-based assay (gentamicin) or an uncalculable result (ketoconazole). This is of particular concern, since gentamicin is one of the few drugs known to cause phospholipidosis in humans.

PLD screen vs. cell-based and in-vivo data

For more detailed comparison with other assays, please read:

Vitovic et al. Assessment of drug-lipid complex formation by a high throughput Langmuir balance and correlation to phospholipidosis. J. Medicinal Chemistry 51(6), 1842-1848 (2008).